| # | Experimental conditions | Cell type used | Tissue derived | Reference |
| 1 | All-trans retinoic acid | hESCs | Smooth muscle cells | Huang et al., 2006 |
| 2 | Co-culture with fetal liver stromal cells | hESCs | Functional erythrocytes | Ma et al., 2008 |
| 3 | Transient reactivation of c-Myc after reprogramming | Human dermal fibroblast derived hiPSCs | Megakaryocytes and Platelets | Takayama et al., 2010 |
| 4 | Sequential treatment with activin A + BMP4 + FGF2 + HGF | Fibroblast derived hiPSC | Hepatocyte-like cells | Si-Tayeb K et al, 2010 |
| 5 | Mouse ESCs treatment with various concentrations of Simvastatin | Osteogenic Progenitors | Successful osteogenic differentiation | Pagkalos et al., 2010 |
| 6 | Pro-intestinal culture + activin + Wnt3A+ FGF4 | hiPSCs and hESCs | Intestinal tissue | Spence et al., 2011 |
| 7 | Feeder free + FGF inhibitor: SU5402, MEK inhibitor: PD184352, and GSK3 inhibitor: CHIR99021) | Rat ESCs | Cardiomyocytes | Cao et al., 2011 |
| 8 | Matrix sandwich + sequential treatment with Activin A, BMP4, & bFGF | Foreskin fibroblast derived hiPSCs | Cardiomyocytes | Zhang J et al., 2012 |
| 9 | Activin + (SB431542+ Noggin) + (EGF + FGF10 + KGF + Wnt3a) | Fibroblast derived hiPSC | Alveolar type I and II cells | Ghaedi M et al., 2013 |
| 10 | Wnt pathway activator, CHIR99021, and either AM580 or TTNPB | hiPSCs/hESCs | Kidney lineage cells | Araoka et al., 2014 |
| 11 | Retinoic acid and BMP4 treatment and culture on Collagen-I & IV dishes | hiPSC | keratinocytes | Kogut et al., 2014 |
| 12 | High (60%) Oxygen culture conditions | Mouse ESCs and hiPSCs | Endocrine progenitors (Insulin producing) | Hakim et al., 2014 |